Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis
Primary cutaneous amyloidosis (PCA) is a chronic, severely pruritic dermatosis characterized by amyloid deposition in the dermis. There is currently no standardized treatment for PCA, and its clinical management remains challenging. Ivarmacitinib, a novel, highly selective oral Janus kinase 1 (JAK1)...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2026-05-01
|
| Cyfres: | Frontiers in Medicine |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1803727/full |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|